CognitionBB-HealthNCT05542199
Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
A study testing Multicomponent nutrition supplement (MCNS) and Behavioral weight loss program in people with Cognition and Obesity, run by Tufts University at 1 site in United States.
Trial summary
The goal of the trial is to determine the feasibility of implementing a specific nutrition regimen used alone or in combination with a behavioral weight loss (WL) intervention on cognition and cerebral blood flow in older adults at risk of cognitive decline. Read more about this study
- Who is it for?
- Ages 55 to 85 yearsHealthy volunteers can take part
- What is being tested?
- Multicomponent nutrition supplement (MCNS) and Behavioral weight loss program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Sep 2022to 23 Feb 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Major inclusion criteria:
- Adult women and men aged 55-85 years.
- BMI of 27.0-39.9 kg/m2 at screening (higher BMIs not included at this time to facilitate program adherence);
- Scores of 34 or greater on the Modified Telephone Interview for Cognitive Status (TICS-M) at screening (85). The purpose of this screen is to ensure that participants can give consent and adhere to the study requirements, including the outcomes testing.
- Willing to be randomized and participate in all study components, including consuming the foods and supplements, participating in the WL intervention or control meetings, being available for outcome assessments, using the provided home Wi-Fi scale and activity monitor daily, and completing questionnaires, as well as providing the login information for scales and activity monitor so investigators can download the data.
- Satisfactory screening review of health history questionnaire by nursing staff for relevant factors including no evidence of exclusions listed below. This will include verbal confirmation of completing a course of vaccination against COVID-19 (two doses plus one booster prior to screening visit). The reason for this study component is that live group meetings are planned with other participants, and this will reduce participant risk.
- Has access to computer or smartphone with Wi-Fi and possesses a freezer at home with space for supplement storage.
- Rates representative food with characteristics of the MCNS and control foods at least 4 on a 5-point scale of liking at screening, and reports that they are willing to consume the food daily.
- Average energy intake in 3 24-h dietary recalls is within physiological (i.e., plausible) range.
Major exclusion criteria:
- >25% percentile in most recent data for US adult population intake for reported DHA/EPA in screening questionnaire for rich food sources, which is equivalent to 2 or more servings of fatty fish/month (86, 87).
- Regularly taking a multivitamin, cacao/cocoa supplement, choline supplement, DHA/EPA supplement, or any supplement advertised for brain health or cognitive function (>1/week). Washout period of 2 months accepted.
- Does not like, or alternatively reports eating >1 serving per week of >60% chocolate or cocoa.
- Severe cardiovascular disease including stroke, heart failure, coronary bypass and valve replacement, coronary bypass or any surgical procedures or signs and symptoms of current severe cardiovascular disease.
- History of neurological brain disease, including stroke, seizure disorders, traumatic brain injury (moderate to severe); including prior diagnosis of a neurodegenerative disease including AD and Parkinson's disease, frontotemporal dementia. Moderate traumatic brain injury is defined by an injury with loss of consciousness.
- Major psychiatric disorder history (schizophrenia, bipolar affective disorder, intractable depression).
- Inadequately controlled hypertension at the discretion of study MD or RN
- Diabetes Type 1 \& Type 2 or use of any pharmacological treatment for diabetes or HbA1c >6.5 at screening.
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol. This includes the lost of smell or taste.
- History of stomach or bowel resection (other than appendectomy), gastric bypass, or other bariatric weight loss procedure
- GI diseases, conditions or meds known to influence GI absorption including active peptic ulcer disease or inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), Celiac disease, Cystic Fibrosis, malabsorption disorders, gallbladder disease, acute or chronic pancreatitis or Pancreatic insufficiency
- Chronic kidney disease or history of kidney stones
- History of diagnosed eating disorder anorexia, bulimia or binge-eating
- Active treatment for cancer (except non-melanoma skin cancer) of any type in ≤ 3 year.
- Thyroid disease or other significant endocrine disorder
- Uncontrolled hypercholesterolemia.
- History of acute or chronic pancreatitis or gall bladder disease.
- Metabolic disorders or conditions that interfere with nutrient absorption (such as Phenylketonuria, Maple Syrup Urine Disease, glucose-galactose malabsorption, ornithine transcarbamylase deficiency or hypophosphatemic rickets.)
- Dose adjustment to statin or antihypertensive medication within the past 3 months
- Screening lab results outside the normal parameters that may interfere with study outcomes at the discretion of study MD
- Inadequate venous access or history of a bilateral mastectomy with nodal dissection
- Recent history of inflammatory diseases (for example: rheumatoid arthritis, lupus)
- Active WL, or weight change > 4 kg in past 6 months.
- Consuming a restrictive diet (e.g. gluten-free, vegan, Paleolithic diet).
- Self-reported allergy to any ingredient in the provided intervention foods.
- Self-reported severe allergy to adhesives.
- Unwilling to use a mobile phone or computer with videoconference software to participate in intervention group meetings. Unwilling to eat on camera.
- Reports of consumption of > 2 alcoholic drinks per day on average or >14/week (168oz beer/56oz wine/14oz hard liquor.)
- Reports of consumption of > 2 cups of green or black tea per day on average.
- Reports of use of recreational and/or illegal drugs.
- Regular smoking or vaping tobacco or marijuana including the use of edibles within the last 6 months (greater than once a week)
- Non-English speakers.
- No social security number (required for stipend payment).
Trial locations and contacts
1 site in 1 country.
United States1 site
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
Boston, Massachusetts, 02111
About this study
Official title: Food Supplement Approach for Prevention of Age-associated Cognitive Decline in Older Adults With Obesity: the Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
The goal of the trial is to determine the feasibility of implementing a specific nutrition regimen used alone or in combination with a behavioral weight loss (WL) intervention on cognition and cerebral blood flow in older adults at risk of cognitive decline.
- Being tested
- Multicomponent nutrition supplement (MCNS), Behavioral weight loss program
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multicomponent nutrition supplement (MCNS)Other
Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
Behavioral weight loss programBehavioural
Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
| Study group | Role | What they receive |
|---|---|---|
| +MCNS+WL | Active comparator | This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention. Receives: Other: Multicomponent nutrition supplement (MCNS); Behavioral: Behavioral weight loss program |
| -MCNS+WL | Placebo comparator | This group receives the placebo nutrition supplement and the behavioral weight loss intervention. Receives: Behavioral: Behavioral weight loss program |
| +MCNS-WL | Active comparator | This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes). Receives: Other: Multicomponent nutrition supplement (MCNS) |
| -MCNS-WL | No intervention | This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive function
Change in age-sensitive cognitive composite z-score from baseline, based on well-established standardized scores on 5 neuropsychological tests (Controlled Oral; Word Association Test, Digit Symbol Substitution Test; Stroop Interference Test; Trails Making Tests A and B)
Measured: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Secondary outcomes (4)
Microvascular cerebral blood flow in fasting state
Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fasting state
Measured: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Microvascular cerebral blood flow in fed state
Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fed state
Measured: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Macrovascular cerebral blood flow velocity in fasting state
Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fasting state
Measured: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Macrovascular cerebral blood flow velocity in fed state
Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fed state
Measured: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2022
- Study start13 Sep 2022
- Primary completion23 Feb 2024
- Study completion23 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CognitionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- A 2x2 factorial design in which participants are assigned to the multicomponent nutrition supplement or a placebo, and to participation in a behavioral weight loss intervention or to a wait-list control
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tufts University
- Sponsor type
- University, hospital or other
- Collaborators
- Massachusetts General Hospital, University of Florida, University of New Hampshire
- Responsible party
- Sponsor
- Investigators
- Susan B. Roberts, Ph.D., Principal investigator, Jean Mayer USDA Human Nutrition Research Center on Aging
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05542199
- Sponsor's protocol ID
- 2273
- Acronym
- BB-Health
- Status last verified
- Sep 2023
- First submitted
- 9 Aug 2022
- Last updated
- 6 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data will be shared consistent with NIH policies.
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Food Supplement Approach for Prevention of Age-associated Cognitive Decline in Older Adults With Obesity: the Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
- ClinicalTrials.gov ID
- NCT05542199
- Acronym / sponsor ID
- BB-Health / 2273
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- Tufts UniversityUniversity, hospital or other
- Collaborators
- Massachusetts General Hospital, University of Florida, University of New Hampshire
- Study start
- 13 Sep 2022 (actual)
- Primary completion
- 23 Feb 2024 (actual)
- Study completion
- 23 Feb 2024 (actual)
- First posted
- 15 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the trial is to determine the feasibility of implementing a specific nutrition regimen used alone or in combination with a behavioral weight loss (WL) intervention on cognition and cerebral blood flow in older adults at risk of cognitive decline.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- A 2x2 factorial design in which participants are assigned to the multicomponent nutrition supplement or a placebo, and to participation in a behavioral weight loss intervention or to a wait-list control
| Arm | Type | Receives |
|---|---|---|
| +MCNS+WL | Active comparator | Other: Multicomponent nutrition supplement (MCNS), Behavioral: Behavioral weight loss programThis group receives the multicomponent nutrition supplement and the behavioral weight loss intervention. |
| -MCNS+WL | Placebo comparator | Behavioral: Behavioral weight loss programThis group receives the placebo nutrition supplement and the behavioral weight loss intervention. |
| +MCNS-WL | Active comparator | Other: Multicomponent nutrition supplement (MCNS)This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes). |
| -MCNS-WL | No intervention | –This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes) |
Who may qualify
- Ages
- 55 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multicomponent nutrition supplement (MCNS)Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition. | Other | +MCNS+WL, +MCNS-WL |
| Behavioral weight loss programEnrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program. | Behavioural | +MCNS+WL, -MCNS+WL |
Primary outcome
Cognitive function
Time frame: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Change in age-sensitive cognitive composite z-score from baseline, based on well-established standardized scores on 5 neuropsychological tests (Controlled Oral; Word Association Test, Digit Symbol Substitution Test; Stroop Interference Test; Trails Making Tests A and B)
4 secondary outcomes
Microvascular cerebral blood flow in fasting state
Time frame: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Microvascular cerebral blood flow in fed state
Time frame: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Macrovascular cerebral blood flow velocity in fasting state
Time frame: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Macrovascular cerebral blood flow velocity in fed state
Time frame: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2025.
- Individual participant dataSharing planned: Yes. De-identified data will be shared consistent with NIH policies.
Related trials for Cognition
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan B. Roberts, Ph.D. principal investigator
Jean Mayer USDA Human Nutrition Research Center on Aging
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multicomponent nutrition supplement (MCNS) and Behavioral weight loss program in people with Cognition and Obesity, run by Tufts University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive function (time frame: Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2025.